p38 MAP Kinase Inhibitors Program for Rheumatoid Arthritis (RA)
Well-validated therapeutic target for inflammation
Large market opportunity across multiple indications (Inflammation ~ $14 B)*
No small-molecule p38 MAP Kinase inhibitor on the market
* Source: www.nature.com/reviews/drugdisc March 2003